DDInter1045 DDInter1676
Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity. Levamlodipine was granted FDA approval on 19 December 2019.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Levamlodipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Levamlodipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Levamlodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tyropanoic acid
Levamlodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Levamlodipine {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Levamlodipine {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Levamlodipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Levamlodipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Levamlodipine may lead to a major life threatening interaction when taken with Enzalutamide
Levamlodipine may lead to a major life threatening interaction when taken with Apalutamide